Resulted in a reduction of serum cholesterol of around 80 percent.

AMT reports positive preclinical data from cholesterol targeting AAV gene therapy study – Gene Therapy Vector Successfully Delivers shRNA Into Liver Cells Amsterdam Molecular Therapeutics a world innovator in gene therapy, today reported positive preclinical data from a scholarly study using an AAV gene therapy product to lower cholesterol. The data show a single dosage of the gene therapy holding a short hairpin RNA to silence Apolipoprotein B100 , resulted in a reduction of serum cholesterol of around 80 percent, without any symptoms of toxicity. These data validate AMT’s technology system as a powerful tool for successful gene silencing within target cells .

We start to see the UF Wellness Cancer Middle at Orlando Health as the model for extra proton centers AMS is usually developing. Dr. That in December 2013 Bates noted, Mevion announced that the world's initial MEVION S250 proton therapy treatment was sent to a patient in the S. Lee Kling Middle for Proton Therapy at the Siteman Cancer Center at Barnes-Jewish Medical center and Washington University College of Medication in St. Louis, the initial site for the machine. This was followed by the initial MEVION S250 proton therapy treatment delivered to a pediatric individual at Barnes-Jewish Medical center in February 2014.